Skip to main content

Table 2 Characteristics of patients included in the analysis and comparison between patients found within a large cluster (≥10 patients) or with a transmission link to patients without these observed connections for determined associations with P-value ≤ 0.1

From: Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe

  Total population % In cluster (n ≥ 10) % Not in cluster % P-value2 With a local transmission link (n = 2–39) % No link % P-value2
Patients             
   223 52.2%1 146 65.5% 77 34.5%   180 80.7% 43 19.3%  
Gender              
  Male 210 94.2% 141 67.1% 69 32.9% 0.0761 170 81.0% 40 19.0% 0.9488
  Female 13 5.8% 5 38.5% 8 61.5%   10 76.9% 3 23.1%  
Year of diagnosis             
  2000–2004 45 20.2% 23 51.1% 22 48.9% 0.0388 31 68.9% 14 31.1% 0.0479
  2005–2008 86 38.6% 60 69.8% 26 30.2% 0.3555 74 86.0% 12 14.0% 0.1514
  2009–2012 92 41.3% 63 68.5% 29 31.5% 0.5178 75 81.5% 17 18.5% 0.9391
Country of origin             
  Slovenia 174 78.0% 122 70.1% 52 29.9% 0.2919 148 85.0% 26 15.0% 0.0479
  Other 15 6.7% 8 53.3% 7 46.7%   9 60.0% 6 40.0%  
  Unknown 34 15.3% 16 47.1% 18 52.9%   23 67.6% 11 32.4%  
Origin of the virus3             
  Slovenia 131 58.7% 105 80.2% 26 19.8% <0.0001 4 120 91.6% 11 8.4% <0.0001 4
  Other 36 16.1% 11 30.6% 25 69.4%   19 52.7% 17 46.3%  
  Unknown 56 25.1% 30 53.6% 26 46.4%   41 73.2% 15 26.8%  
SDRMs             
  Detected 8 3.6% 2 25.0% 6 75.0% 0.0431 3 37.5% 5 62.5% 0.0153
  Not detected 215 96.4% 144 67.0% 71 33.0%   177 82.3% 38 17.7%  
  1. 1proportion among all newly diagnosed HIV-1 patients in the period 2000–2012 in Slovenia.
  2. 2for significance testing, the Fisher exact test was employed for categorical data and t-statistics for continuous data. P-values ≤ 0.05 are shown in bold.
  3. 3the origin of the virus is determined according to the country where the infection most probably occurred, as reported in the patients’ questionnaires.
  4. 4significant characteristic after employing a Bonferroni correction, at a significance level of <0.0033.
  5. SDRMs = surveillance for drug resistance mutations, n = number of patients in a transmission cluster.